Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.095,74 -983,96 (-2,58%) EUR/USD
1,0635 -0,0011 (-0,11%) Bitcoin EUR
58.267,25 +257,76 (+0,44%) CMC Crypto 200
1.287,16 +401,63 (+44,14%)
SpringWorks Therapeutics, Inc. (SWTX)
Dopo ore:
| Chiusura precedente | 44,11 |
| Aperto | 43,93 |
| Denaro | 42,39 x 100 |
| Lettera | 42,51 x 100 |
| Min-Max giorno | 42,42 - 44,34 |
| Intervallo di 52 settimane | 18,00 - 53,92 |
| Volume | |
| Media Volume | 1.116.929 |
| Capitalizzazione | 3,145B |
| Beta (5 anni mensile) | 0,82 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,15 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 66,75 |
GlobeNewswireSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (
- GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12, 2023 beginning at 11:20 a.m. PT / 2:20 p.m. ET. To access the live webcast, please visit the E
- GlobeNewswire
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023STAMFORD, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has updated the Prescription Drug User Fee Act (PDUFA) action date for t
